PTC Therapeutics (FRA:BH3) Float Percentage Of Total Shares Outstanding: 73.61% (As of Jul. 09, 2026)


FRA:BH3 PTC Therapeutics Inc FRA:BH3
52 GF Score
Price €77.00
GF Value €31.18
! 9 Warning Signs
View Full Analysis

What is PTC Therapeutics Float Percentage Of Total Shares Outstanding?

PTC Therapeutics FRA:BH3 +4.88% 52 Float Percentage Of Total Shares Outstanding is 73.61% as of Jul. 09, 2026. GuruFocus rates FRA:BH3 with a GF Score™ of 52/100 and a GF Value™ of €31.18. The stock has 9 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PTC Therapeutics's float shares is 61.06 Mil. PTC Therapeutics's total shares outstanding is 82.95 Mil. PTC Therapeutics's float percentage of total shares outstanding is 73.61%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PTC Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PTC Therapeutics's Institutional Ownership is 67.66%.

FRA:BH3
52GF Score
PTC Therapeutics Inc FRA:BH3
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PTC Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

PTC Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=61.06/82.95
=73.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 73.61% mean?
PTC Therapeutics (FRA:BH3) has a Float Percentage Of Total Shares Outstanding of 73.61% as of Jul. 09, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on PTC Therapeutics and its competitors.
Is PTC Therapeutics' Float Percentage Of Total Shares Outstanding too high?
PTC Therapeutics' current Float Percentage Of Total Shares Outstanding is 73.61%. Overall, PTC Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Float Percentage Of Total Shares Outstanding compare to SRRK and COGT?
PTC Therapeutics' Float Percentage Of Total Shares Outstanding of 73.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current Float Percentage Of Total Shares Outstanding is 73.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current Float Percentage Of Total Shares Outstanding of 73.61%. The stock's GF Value™ is €31.18, compared to a current price of €77.00 — trading 147% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 73.61%. PTC Therapeutics' overall GF Score™ is 52/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current Float Percentage Of Total Shares Outstanding is 73.61% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €77.00 is trading 147% above its estimated GF Value™ of €31.18.

Key valuation signals for FRA:BH3:

  • Float Percentage Of Total Shares Outstanding: 73.61%
  • GF Value™: €31.18 vs. price of €77.00 (147% above fair value)
  • GF Score™: 52/100 with 9 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
52GF Score

Get the complete analysis for FRA:BH3

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.00
Price
€31.18
GF Value